Outlook 2017

barring unforeseen circumstances

The Straumann Group expects the global implant market to grow at a similar rate (3-4%) in 2017 and is confident that it can continue to outperform by achieving organic revenue growth in the high-single-digit range. Despite further investments in strategic growth initiatives and assuming that currency exchange rates remain fairly stable, the expected revenue growth and operational leverage should lead to further improvements in the (organic*) operating profit margin.

* Excluding the effects of the Medentika and the Equinox consolidation/acquisition.